TEVA -- Zukunft mit Generika

Seite 1 von 57
neuester Beitrag: 20.09.18 20:21
eröffnet am: 27.08.08 18:01 von: 14051948Ki. Anzahl Beiträge: 1425
neuester Beitrag: 20.09.18 20:21 von: tazmaraz Leser gesamt: 365650
davon Heute: 377
bewertet mit 9 Sternen

Seite: Zurück 1 | 2 | 3 | 4 |
55 | 56 | 57 | 57  Weiter  

27.08.08 18:01

29411 Postings, 4221 Tage 14051948KibbuzimTEVA -- Zukunft mit Generika

Über das israelische Pharmaunternehmen TEVA muß man nicht viel sagen,der auf Generika spezialisierte Pharmakonzern gehört zu den bekanntesten Unternehmen Israels.


Neue Studienergebnisse zu Parkinson Medikament

ADAGIO Trial Results Show Teva´s AZILECT(R) 1 mg Tablets Slow Progression of Parkinson´s Disease

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA  videos nachrichten) announces that results of the phase III ADAGIO trial were presented today during the 12th Congress of European Federation of Neurological Societies (EFNS) in Madrid, Spain as part of a "Late Breaking News" session.

The ADAGIO study showed that Parkinson´s disease (PD) patients who took AZILECT(R) (rasagiline) 1mg tablets once-daily upon entry into the trial, demonstrated a significant improvement compared to those who initiated the drug 9 months later.

The 1mg dose met all three primary endpoints, as well as the secondary endpoint, with statistical significance.  The primary analysis included three hierarchical endpoints based on Total-UPDRS (Unified Parkinson´s Disease Rating Scale) scores:

A) superiority of slopes in weeks 12-36 (-0.05; p=0.013, 95%CI -0.08,-0.01),

B) change from baseline to week 72 (-1.7 units; p=0.025, 95%CI -3.15,-0.21), and

C) non-inferiority of slopes (0.15 margin) in weeks 48-72 (0.0; 90%CI -0.04,0.04).

The safety profile of AZILECT(R) seen in the ADAGIO study was similar to previous experience with AZILECT(R).

Main results were presented at the congress by Professor Olivier Rascol, M.D., Ph.D., Department of Clinical Pharmacology, University Hospital, Toulouse, France, one of two principal investigators of the trial.

"The rigorous trial design and the fact that all three primary endpoints were met with statistical significance reinforce the quality of the data, supporting the potential for AZILECT(R) to have an effect on disease progression," said Prof. Rascol.

"The successful outcome of the study provides further rationale for the early use of AZILECT(R) among Parkinson´s disease patients," he added. "Delaying disease progression is the most important unmet need in the management of Parkinson´s disease," stated Prof. C. Warren Olanow, professor and chairman of the Department of Neurology at the Mount Sinai School of Medicine, New York, NY, and ADAGIO co-principal investigator.

"The ADAGIO study, the first of its kind, was prospectively designed to demonstrate if AZILECT(R) can slow down the progression of Parkinson´s disease. Results of the study show that early treatment with once-daily rasagiline 1mg tablets provided significant clinical benefits that were not obtained by those patients where initiation of AZILECT(R) therapy was delayed by nine months."

 The ADAGIO study, one of the largest conducted in PD, included 1,176 patients with very early Parkinson´s disease in 14 countries and 129 medical centers who were randomized to receive rasagiline 1 or 2 mg/day for 72 weeks (early start) or placebo for 36 weeks followed by rasagiline 1 or 2 mg/day for 36 weeks (delayed start).

Description of trial results can be found online ( in the abstract submitted by Prof. Olanow and Prof. Rascol to the 133rd Annual Meeting of the American Neurological Association, Salt Lake City, UT, September 21-24, 2008.

Prof. Olanow will be presenting these results during the Works in Progress poster session on Tuesday, September 23, 2008. The abstract was also chosen to be presented orally by Prof. Olanow on Tuesday from 11:45am-noon.

Teva intends to submit these results to the regulatory authorities in the U.S. and Europe. Based on these results, Teva will work with the regulatory authorities to incorporate the results into the label for AZILECT(R).

For more information on AZILECT(R), please visit

About the Study  

ADAGIO is a randomized, multi-center, double-blind, placebo-controlled, parallel-group study prospectively examining rasagiline´s potential disease-modifying effects in 1,176 patients with early, untreated Parkinson´s disease.

Patients from 129 centers in 14 countries were randomized to early-start treatment (72 weeks rasagiline 1 or 2 mg once daily) or delayed-start treatment (36 weeks placebo followed by 36 weeks rasagiline 1 or 2 mg once daily (active treatment phase)).

The primary analyses of the trial were based on change in total UPDRS (Unified Parkinson´s Disease Rating Scale) and included slope superiority of rasagiline over placebo in the placebo-controlled phase, change from baseline to week 72, and non-inferiority of early-start vs. delayed-start slopes during weeks 48-72 of the active phase. UPDRS is the most commonly used rating scale to assess disease status.

About AZILECT (R)  

AZILECT(R) 1mg tablets (rasagiline tablets) are indicated for the treatment of the signs and symptoms of Parkinson´s disease both as initial therapy alone and to be added to levodopa later in the disease. AZILECT(R) 1mg tablets are currently available in 30 countries, including the US, Canada, Israel, Mexico, and most of the EU countries.

About Parkinson´s Disease

Parkinson´s disease is an age-related degenerative disorder of the brain.

Symptoms can include: tremor, stiffness, slowness of movement, and impaired balance. An estimated four million people worldwide suffer from the disease, which usually affects people over the age of 60.

About Teva  

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world´s leading generic pharmaceutical company.

The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products.

Over 80 percent of Teva´s sales are in North America and Europe.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:  This release contains forward-looking statements. Such statements are based on management´s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva´s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements, including statements relating to the results of the ADAGIO phase III trial and the potential efficacy or future market or marketability of AZILECT(R).

Following further analysis, Teva´s interpretation of the results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release as there can be no guarantee that the results from the phase III trial discussed in this press release will be confirmed upon full analysis of the results of the trial and additional information relating to the safety, efficacy or tolerability of AZILECT(R) may be discovered upon further analysis of data from the phase III trial.

Even if the results described in this release are confirmed upon full analysis of the ADAGIO study, we cannot guarantee that AZILECT(R) will be approved for marketing in a timely manner, if at all, by regulatory authorities in the EU or in the U.S. Additional risks relating to Teva and its business are discussed in Teva´s Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

"Ein Deutscher ist ein Mensch,der keine Lüge aussprechen kann, ohne sie selbst zu glauben"(Theodor W. Adorno)
Seite: Zurück 1 | 2 | 3 | 4 |
55 | 56 | 57 | 57  Weiter  
1399 Postings ausgeblendet.

15.09.18 00:26

189 Postings, 101 Tage amorphis;-)

15.09.18 00:32

189 Postings, 101 Tage amorphisFDA Approved Drug Products

Drugs@FDA: FDA Approved Drug Products

Biologic License Application (BLA): 761089 


15.09.18 09:38

189 Postings, 101 Tage amorphisIch dachte hier wäre etwas...

...bessere Stimmung nach dieser Blockbuster Zulassung ;-)
Gut möglich das wir nächste Woche neue Jahreshochs sehen.  

15.09.18 16:41

73 Postings, 2834 Tage tazmarazFreue mich auch über die News

Da bin ich mal gespannt auf nächste Woche !
Hoffentlich wird es kein sell on good news für die großen Marketmaker die erstmal den Kurs auf unter 21 USD gesteuert haben , waren dann schon wieder 20- 30 % wenn es noch mehr anzieht am Montag / Dienstag ...
Ich hatte mal wieder zu früh verkauft und bin dann wieder zu früh eingestiegen und konnte die Spanne nicht annähernd ausnutzen wie ich es mir gewünscht hätte ... aber solange die 30USD bald mal kommen wäre ich nicht mehr traurig drum  

15.09.18 17:56

189 Postings, 101 Tage amorphisseekingalpha

nachbörslich fast bei 25$...denke eher wir sehen nächste Woche neue Jahreshochs als das wir sell on good news erleben. Haben vom Jahreshoch ja bereits deutlich abgegeben.  

15.09.18 20:02

73 Postings, 2834 Tage tazmarazSeekingalpha

Das  Artikel Update mit den angepeilten Preisen die erzielt werden sollen ist vielversprechend !
Glück auf  

16.09.18 00:34

73 Postings, 2834 Tage tazmaraz

Also angesagtes Marktpotential von ca 14 Millionen Patienten allein in den USA mit Quartalsumsatz von 1725 USD pro Dosis - da steckt ordentlich Umsatz hinter ... bin gespannt auf die Reaktion der nächsten Tage , und wie lange Novartis noch braucht um sein Mittel nachzuschieben ...

16.09.18 11:38

189 Postings, 101 Tage amorphisImportant Validation

With the drug?s approval, Schultz enhanced his credibility with investors, some of whom were skeptical that the company would be able to begin selling the drug on time and thus lose more ground to Amgen Inc.?s Aimovig, which has been on the market since May. Teva shares rose 6 percent after the market closed in New York on Friday.

?Hitting this target is very important validation for management?s credibility,? Evercore ISI analyst Umer Raffat wrote in an emailed note to clients.

Ajovy will cost as much as Aimovig. ?We looked at the value that we believe we will bring to patients and migraine sufferers, and we thought a parity price to Aimovig at $575 a month was appropriate,? said Brendan O?Grady, executive vice president and head of Teva?s commercial operations in North America.

?We think this is a huge value for a patient population with a tremendous need that payers will look at this and give pretty broad and open access to the entire class,? O?Grady said.

The competition for the multi-billion dollar market is set to heat up further with the FDA expected to decide on another migraine therapy from Eli Lilly & Co. next month. ?Marketing and patient access? will be what determines who pulls ahead since the companies offer ?similar products,? according to a Bloomberg Intelligence note.  

16.09.18 23:43

189 Postings, 101 Tage amorphisIch weiß auch gar nicht...

...wie manch ein Analyst bei Ajovy auf ein Umsatzpotential von 500 Mio bis 2022 kommen kann. Der Markt ist ca 8 bis 10 Mrd $ allein in den USA groß. Es gibt neben Teva derzeit noch 2 weitere Player auf dem Markt:

- Amgen
- Eli Lilly (Zulassung in Kürze)

Teva bietet als einzige Firma eine "quarterly dose" an. Ich denke der Umsatz wird bis 2022 deutlich höher sein.  

17.09.18 08:22

105 Postings, 3053 Tage Investmenttrader_Li.Auf den guten alten...

Warren ist einfach verlass. Euch allen fette Gewinne und eine schöne Woche!  

17.09.18 10:22

25 Postings, 58 Tage SynopticAuf den guten alten... Warren ist einfach verlass.

Hoffen wir, dass diese Aussage auf alle seine neuen Investments zu trifft.


17.09.18 15:51

189 Postings, 101 Tage amorphisHier wird aber versucht... allen Mitteln den Kurs unten zu halten:

Untergewichten - 13$
das ich nicht lache ;-)  

17.09.18 21:56

73 Postings, 2834 Tage tazmarazAmorphis

Die Hoffnung stirbt zuletzt ;)
Mal schauen was die Woche noch so bringt,
Leider hatte ich so was schon im Gefühl ...  

18.09.18 08:05

1303 Postings, 319 Tage KörnigDer Kurs ist ordentlich Abverkauf worden,

nachdem es schon sehr gut ausgesehen hatte. Die Hauptsache ist für mich das es heute wieder steigt.  

18.09.18 10:48

189 Postings, 101 Tage amorphisDie Hauptsache... für mich das die zwei Zulassungen erteilt wurden. Steigen wird der Kurs mittelfristig von alleine ;-)  

18.09.18 21:19

1303 Postings, 319 Tage KörnigHeute sieht es wieder grün aus! Habe

zwar nur 200 Stück gekauft, aber aus dem Minus bin ich glaube ich auch fast wieder raus.  

18.09.18 21:56

25 Postings, 58 Tage SynopticWas ist denn heute los?

Haben gestern alle geschlafen?  

18.09.18 22:44

73 Postings, 2834 Tage tazmarazIch denke nicht :Trumpsche Zoll Ansagen Reaktion

Abgewartet würde ich sagen, und da der Markt trotz neuer Zölle nicht komplett gecrasht ist, wurde heute gekauft ...  

18.09.18 22:45

73 Postings, 2834 Tage tazmarazKörnig

Das freut mich ! Erst Recht dass du nach dem hohem Einstieg nicht direkt geschmissen hast ;)

19.09.18 16:18

1303 Postings, 319 Tage Körnigtazmaraz

Danke! Habe ein durchschnitts EK von 21,64 ?/Stk., habe grade mal nachgeschaut. Mache mir bei diesem Invest mal so gar keine Sorgen:) Leider habe ich andere Titel für kurzfristige Gewinne kaufen müssen, sonst hätte ich hier auch nachgelegt.  

19.09.18 17:15

25 Postings, 58 Tage Synoptices bleibt spannend...

Werden wir heute die 25 USD von oben sehen?    

20.09.18 20:17

189 Postings, 101 Tage amorphis@Synoptic

heute könnte es passieren ;-)
Bleibt morgen noch der Tag für ein neues Jahreshoch.  

20.09.18 20:21

73 Postings, 2834 Tage tazmarazIch drück die Daumen !

Danke für den Link Amorphis !  

Seite: Zurück 1 | 2 | 3 | 4 |
55 | 56 | 57 | 57  Weiter  
   Antwort einfügen - nach oben